Regulatory T cells and cancer: an undesired tolerance Didier Ducloux Kidney International Volume 86, Issue 1, Pages 16-18 (July 2014) DOI: 10.1038/ki.2014.46 Copyright © 2014 International Society of Nephrology Terms and Conditions
Figure 1 Defect in cancer immune surveillance in transplant patients. Both immunosuppressive drugs and an increase in tumor-driven Tregs (i.e., migration and expansion of naturally occurring Tregs (nTregs) or conversion and expansion of induced Tregs (iTregs)) contribute to impair immune responses against cancer in transplant patients. Therapeutic approaches should target both mechanisms. CNI, calcineurin inhibitor; mTORi, mTOR inhibitor; NK, natural killer; Treg, regulatory T cell. Kidney International 2014 86, 16-18DOI: (10.1038/ki.2014.46) Copyright © 2014 International Society of Nephrology Terms and Conditions